MX2021003549A - Anticuerpos dobles especificos. - Google Patents

Anticuerpos dobles especificos.

Info

Publication number
MX2021003549A
MX2021003549A MX2021003549A MX2021003549A MX2021003549A MX 2021003549 A MX2021003549 A MX 2021003549A MX 2021003549 A MX2021003549 A MX 2021003549A MX 2021003549 A MX2021003549 A MX 2021003549A MX 2021003549 A MX2021003549 A MX 2021003549A
Authority
MX
Mexico
Prior art keywords
specific antibodies
dual specific
antibodies
antibody
nucleic acid
Prior art date
Application number
MX2021003549A
Other languages
English (en)
Inventor
Germaine Fuh
Patrick Koenig
Chingwei V Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2021003549A publication Critical patent/MX2021003549A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención brinda anticuerpos específicos dobles y métodos de fabricación y uso de estos anticuerpos. En general, los anticuerpos específicos dobles se generan mediante identificación de un anticuerpo monoespecífico con residuos VL de región variable de cadena ligera que son electrostáticos o hidrofóbicos y alteración la secuencia de ácido nucleico que codifica uno o más residuos accesibles para el solvente en el VH del anticuerpo solo o en combinación con alteración de la secuencia de ácido nucleico que codifica el VL del anticuerpo. Se expresan el VH y el VL alterado y se seleccionan anticuerpos específicos dobles o fragmentos de unión a antígeno de estos. También se brindan ejemplos de anticuerpos específicos dobles, así como métodos de uso de los anticuerpos.
MX2021003549A 2013-12-20 2016-05-19 Anticuerpos dobles especificos. MX2021003549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919552P 2013-12-20 2013-12-20
US201461946547P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
MX2021003549A true MX2021003549A (es) 2021-05-27

Family

ID=52293284

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006529A MX2016006529A (es) 2013-12-20 2014-12-18 Anticuerpos dobles especificos.
MX2021003549A MX2021003549A (es) 2013-12-20 2016-05-19 Anticuerpos dobles especificos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016006529A MX2016006529A (es) 2013-12-20 2014-12-18 Anticuerpos dobles especificos.

Country Status (10)

Country Link
US (2) US10683348B2 (es)
EP (1) EP3083682B1 (es)
JP (2) JP7325166B2 (es)
KR (2) KR20230155605A (es)
CN (2) CN114702594A (es)
BR (1) BR112016011027A2 (es)
CA (2) CA2931113C (es)
MX (2) MX2016006529A (es)
RU (2) RU2020129339A (es)
WO (1) WO2015095539A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
EP3579848A4 (en) 2017-02-08 2021-03-03 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR ACTIVATING NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES FOR TREATING CANCER
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2018162376A1 (en) * 2017-03-07 2018-09-13 F. Hoffmann-La Roche Ag Method for discovery of alternative antigen specific antibody variants
MX2019011769A (es) 2017-04-03 2019-11-07 Hoffmann La Roche Anticuerpos que se unen a steap-1.
LT3606954T (lt) 2017-04-05 2022-09-26 F. Hoffmann-La Roche Ag Anti-lag3 antikūnai
AU2018340557A1 (en) 2017-09-29 2020-04-09 Jiangsu Hengrui Medicine Co., Ltd. IL-5 antibody, antigen binding fragment thereof, and medical application therefor
MA51302A (fr) 2017-12-21 2021-03-31 Hoffmann La Roche Anticorps se liant à hla-a2/wt1
CN111630063A (zh) 2018-01-31 2020-09-04 豪夫迈·罗氏有限公司 稳定化的免疫球蛋白结构域
CN111655730A (zh) 2018-01-31 2020-09-11 豪夫迈·罗氏有限公司 包含与lag3结合的抗原结合位点的双特异性抗体
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
SG11202009542PA (en) 2018-03-29 2020-10-29 Genentech Inc Modulating lactogenic activity in mammalian cells
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR117727A1 (es) 2018-12-21 2021-08-25 Hoffmann La Roche Anticuerpos que se unen a cd3
WO2020136060A1 (en) 2018-12-28 2020-07-02 F. Hoffmann-La Roche Ag A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
MX2021011530A (es) 2019-03-29 2021-10-22 Jiangsu Hengrui Medicine Co Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.
EP3990646A1 (en) 2019-06-26 2022-05-04 F. Hoffmann-La Roche AG Mammalian cell lines with sirt-1 gene knockout
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
CA3144524A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
CN114423791A (zh) 2019-09-18 2022-04-29 豪夫迈·罗氏有限公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
BR112022008172A2 (pt) 2019-11-15 2022-07-12 Hoffmann La Roche Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
CR20220277A (es) 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos anti-ccl2 biespecifico
CA3161390A1 (en) 2019-12-18 2021-06-24 Tina WEINZIERL Antibodies binding to hla-a2/mage-a4
KR20220118527A (ko) 2019-12-23 2022-08-25 제넨테크, 인크. 아포지질단백질 l1-특이적 항체 및 이용 방법
MX2022008442A (es) 2020-01-15 2022-08-02 Hoffmann La Roche Metodos para disminuir impurezas de procesos de manufacturacion de proteinas recombinantes.
CN115315512A (zh) 2020-03-26 2022-11-08 基因泰克公司 具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
EP4149421A1 (en) 2020-05-15 2023-03-22 F. Hoffmann-La Roche AG Prevention of visible particle formation in parenteral protein solutions
EP4153130A1 (en) 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
CN115697489A (zh) 2020-06-08 2023-02-03 豪夫迈·罗氏有限公司 抗hbv抗体及其使用方法
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CA3176579A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3
MX2022015887A (es) 2020-06-19 2023-01-24 Hoffmann La Roche Anticuerpos que se unen a cd3 y folr1.
AU2021291011A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and CD19
IL299161A (en) 2020-06-24 2023-02-01 Genentech Inc Cell lines resistant to apoptosis
JP2023532764A (ja) 2020-07-07 2023-07-31 エフ． ホフマン－ラ ロシュ アーゲー 治療用タンパク質製剤の安定剤としての代替界面活性剤
KR20230038735A (ko) 2020-07-17 2023-03-21 제넨테크, 인크. 항-notch2 항체 및 이용 방법
WO2022047222A2 (en) 2020-08-28 2022-03-03 Genentech, Inc. Crispr/cas9 multiplex knockout of host cell proteins
TW202223092A (zh) 2020-09-24 2022-06-16 瑞士商赫孚孟拉羅股份公司 具有基因剔除的哺乳動物細胞株
TW202233671A (zh) 2020-10-20 2022-09-01 美商建南德克公司 Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
US20240002483A1 (en) 2020-11-16 2024-01-04 Hoffmann-La Roche Inc. Fab high mannose glycoforms
PE20240819A1 (es) 2020-12-17 2024-04-18 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
JP2024509695A (ja) 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド 多重特異性結合タンパク質分解プラットフォームおよび使用方法
CN117062839A (zh) 2021-03-12 2023-11-14 基因泰克公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
EP4320444A1 (en) 2021-04-09 2024-02-14 F. Hoffmann-La Roche AG Process for selecting cell clones expressing a heterologous polypeptide
TW202305122A (zh) 2021-04-19 2023-02-01 美商建南德克公司 經修飾之哺乳動物細胞
CN117396599A (zh) 2021-05-21 2024-01-12 基因泰克公司 用于生产目的重组产物的经修饰的细胞
CN117500829A (zh) 2021-06-18 2024-02-02 豪夫迈·罗氏有限公司 双特异性抗ccl2抗体
US20230197278A1 (en) 2021-07-13 2023-06-22 Genentech, Inc. Multi-variate model for predicting cytokine release syndrome
CA3219606A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
WO2023117325A1 (en) 2021-12-21 2023-06-29 F. Hoffmann-La Roche Ag Method for the determination of hydrolytic activity
WO2023141445A1 (en) 2022-01-19 2023-07-27 Genentech, Inc. Anti-notch2 antibodies and conjugates and methods of use
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
CA3239182A1 (en) * 2022-05-23 2023-11-30 Zhipeng SU Stable antibody preparation
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability
WO2023232961A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Improved production cells
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024079009A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and proteasome inhibitors
WO2024079015A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and imids
WO2024079010A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and cd38 antibodies
WO2024079069A1 (en) 2022-10-12 2024-04-18 F. Hoffmann-La Roche Ag Method for classifying cells
WO2024110426A1 (en) 2022-11-23 2024-05-30 F. Hoffmann-La Roche Ag Method for increasing recombinant protein expression

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
SK1152003A3 (en) * 2000-06-29 2003-07-01 Abbott Lab Dual specificity antibodies and methods of making and using
EP1399484B1 (en) * 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2755640C (en) * 2009-03-20 2018-05-22 Genentech, Inc. Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
JP5901517B2 (ja) * 2009-05-28 2016-04-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合性タンパク質
JP2014516542A (ja) * 2011-05-27 2014-07-17 デュタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重標的化
MX2015013901A (es) 2013-04-05 2015-12-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.

Also Published As

Publication number Publication date
WO2015095539A1 (en) 2015-06-25
KR20160099086A (ko) 2016-08-19
US20200255512A1 (en) 2020-08-13
KR20230155605A (ko) 2023-11-10
CA3204788A1 (en) 2015-06-25
CN105849124B (zh) 2022-04-12
EP3083682B1 (en) 2024-04-17
KR102597804B1 (ko) 2023-11-07
EP3083682C0 (en) 2024-04-17
CA2931113C (en) 2023-07-11
EP3083682A1 (en) 2016-10-26
JP2020162609A (ja) 2020-10-08
JP2023179409A (ja) 2023-12-19
JP2017501711A (ja) 2017-01-19
CN105849124A (zh) 2016-08-10
CN114702594A (zh) 2022-07-05
US10683348B2 (en) 2020-06-16
BR112016011027A2 (pt) 2017-12-05
CA2931113A1 (en) 2015-06-25
US12006360B2 (en) 2024-06-11
RU2732032C2 (ru) 2020-09-10
JP7325166B2 (ja) 2023-08-14
US20160257744A1 (en) 2016-09-08
MX2016006529A (es) 2016-08-03
RU2020129339A (ru) 2020-10-02
RU2016129247A (ru) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2021003549A (es) Anticuerpos dobles especificos.
CY1125267T1 (el) Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn
AU2019268150A1 (en) Isotyping immunoglobulins using accurate molecular mass
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EP3389683B8 (en) Virus encoding an anti-tcr-complex antibody or fragment
MX2022002364A (es) Anticuerpos anti-pd-l1.
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
EP3243840B8 (en) Bispecific antibody or antibody mixture with common light chains
EP3433277A4 (en) NEW ANTIBODIES AGAINST PD-L1
EP3399989A4 (en) ANTI-LAG3 ANTIBODIES AND ANTIGEN FIXING FRAGMENTS
CR20170026A (es) Anticuerpos anti-tau humanizados
EP3332006A4 (en) NEW ANTI-PD-L1 ANTIBODIES
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
BR112016020518A2 (pt) receptor antigênico quimérico
EP3487888A4 (en) BISPECIFIC ANTI-HER2 ANTIBODIES
WO2016014688A3 (en) Anti-pd-1 antibodies
EP3307777A4 (en) NOVEL ANTI-PD-L1 ANTIBODIES
WO2014165771A3 (en) Anti-il-4 antibodies and bispecific antibodies and uses thereof
CO2017005941A2 (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3532489A4 (en) ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
EP3452107A4 (en) DNA MONOCLONAL ANTIBODIES AGAINST CHECKPOINT MOLECULES
EP3442576A4 (en) HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EP3507307A4 (en) BISPECIFIC ANTIBODIES
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof